Literature DB >> 17310470

Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.

Qing Huang1, Guang-Ji Wang, Jian-Guo Sun, Xiao-Lin Hu, Yi-Hong Lu, Qian Zhang.   

Abstract

A rapid and sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) method has been developed and validated for simultaneous quantification of docetaxel and ketoconazole in rat plasma with paclitaxel as internal standard (IS). The analytes were extracted from rat plasma by using a liquid-liquid extraction technique with ethyl acetate and the LC separation was performed on a Cosmosil-C(18) analytical column (150 mm x 2.0 mm i.d., Nacalai Tesque Inc., Japan). The extracted samples were analyzed with LC/MS/MS, operating in selected reaction monitoring (SRM) mode. The SRM transitions of precursor ions to product ions were 830.3-->549.1 (m/z) for docetaxel, 531.2-->489.3 (m/z) for ketoconazole, and 876.7-->307.9 (m/z) for the IS. The calibration curves were linear over the range of 2-500 ng/mL for docetaxel and 50-20 000 ng/mL for ketoconazole, with coefficients of correlation above 0.999. The limits of quantification for docetaxel and ketoconazole were both 2 ng/mL. The limit of detection for each analyte was 1 ng/mL. The intra- and inter-day precision (CV) of analysis were within 7%, and the accuracy ranged from 95 to 110%. The overall recoveries for docetaxel and ketoconazole were about 89.0% and 91.1%, respectively. The total analysis time was only 9.0 min. This quantitation method was successfully applied to the simultaneous determination of docetaxel and ketoconazole in rat plasma and some potential interaction was found in the current coadministration pharmacokinetic study. This established method was also utilized in the in vitro and in vivo drug-drug interaction study of docetaxel and ketoconazole (to be published).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17310470     DOI: 10.1002/rcm.2903

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  2 in total

1.  Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.

Authors:  Islam R Younis; Daniel J George; Terence J McManus; Herbert Hurwitz; Patricia Creel; Andrew J Armstrong; Jing Jie Yu; Kristina Bacon; Gerald Hobbs; Cody J Peer; William P Petros
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-12       Impact factor: 3.333

2.  Determination of total and unbound docetaxel in plasma by ultrafiltration and UPLC-MS/MS: application to pharmacokinetic studies.

Authors:  Ming-Thau Sheu; Chen-Yuan Wu; Chia-Yu Su; Hsiu-O Ho
Journal:  Sci Rep       Date:  2017-11-06       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.